Plaquenil

(Hydroxychloroquine)

ApprovedSmall molecule

Hydroxychloroquine is used to treat malaria, lupus (an autoimmune disease), and rheumatoid arthritis. It helps reduce inflammation and symptoms like joint pain and skin rashes.[2] Plaquenil is currently approved and in use across 67 indications[4].[1]

Plaquenil is one of 1183 small molecule programs targeting COVID-19. It is currently in Approved.

Indications

313

Total Trials

Active Trials

1,182

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

COVID-19Unknown status

Breast CancerRecruiting

Osteoarthritis, KneeApproved

Lichen PlanusApproved

Coronavirus Infectious DiseaseApproved

Sjogren SyndromeApproved

Chronic Hepatitis C Virus InfectionApproved

Low Grade GliomaApproved

MastocytosisApproved

Chronic Lymphocytic LeukemiaApproved

COVID-19Approved

Unknown status

Breast CancerPhase 2

Recruiting

Osteoarthritis, KneeApproved

Approved

Lichen PlanusApproved

Approved

Coronavirus Infectious DiseaseApproved

Approved

Sjogren SyndromeApproved

Approved

Chronic Hepatitis C Virus InfectionApproved

Approved

Low Grade GliomaApproved

Approved

MastocytosisApproved

Approved

Chronic Lymphocytic LeukemiaApproved

Approved

Showing 10 of 67 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Plaquenil

Jazz Pharmaceuticals

Approved

7 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Efficacy and Safety

NCT06479304

N/ARecruiting

Efficacy and Safety

NCT06479291

N/ARecruiting

Efficacy and Safety

NCT06479317

Recruiting

Pregnancy

NCT04918524

Q1 2027

Phase 2Recruiting

COVID-19

NCT05041907

N/ARecruiting

Type 2 Diabetes

NCT06319560

Clinical

Trials by Indication[1]

COVID-1960 trials

Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora

Unknown status·—·Phase 2·NCT04366089·152 enrolled

A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection

Completed·PProgenaBiome·Phase 2·NCT04335084·254 enrolled

Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Terminated·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT04363827·155 enrolled

Show 57 more trials

Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau·Phase 2·NCT04332094·276 enrolled

Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting

Completed·SSt. Francis Hospital, New York·Phase 4·NCT04370782·18 enrolled

Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19

Unknown status·IIntermountain Health Care, Inc.·Phase 3·NCT04334382·1,550 enrolled

Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19

Withdrawn·UUniversity Hospital, Lille·Phase 3·NCT04372082

Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers

Completed·—·Phase 2·NCT04333225·221 enrolled

Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection

Terminated·SSanford Health·Phase 3·NCT04372017·1 enrolled

Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection

Completed·—·Phase 3·NCT04391127·108 enrolled

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Suspended·PProvidence Health & Services·Phase 4·NCT04334967·13 enrolled

A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients

Terminated·QQueen's Medical Center·Phase 3·NCT04345692·17 enrolled

Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP)

Unknown status·LLouisiana State University Health Sciences Center in New Orleans·Phase 3·NCT04363450·1,700 enrolled

Favipiravir in Hospitalized COVID-19 Patients

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 4·NCT04359615·40 enrolled

Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic

Completed·BBarcelona Institute for Global Health·Phase 3·NCT04331834·275 enrolled

Azithromycin in Hospitalized COVID-19 Patients

Unknown status·SShahid Beheshti University of Medical Sciences·Phase 4·NCT04359316·40 enrolled

Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT

Completed·SShehnoor Azhar·Phase 3·NCT04338698·550 enrolled

Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic

Completed·—·N/A·NCT04668469·600 enrolled

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

Terminated·UUniversity of New Mexico·Phase 1/2·NCT04435808·1 enrolled

Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease

Terminated·UUniversity Hospital, Angers·Phase 3·NCT04325893·259 enrolled

Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO

Suspended·AAssistance Publique - Hôpitaux de Paris·Phase 2/3·NCT04341870·27 enrolled

Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19

Terminated·CChronic Obstructive Pulmonary Disease Trial Network, Denmark·Phase 2·NCT04322396·117 enrolled

ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease

Terminated·—·Phase 3·NCT04329611·148 enrolled

A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Withdrawn·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04379492

Immune Monitoring of Prophylactic Effect of Hydroxychloroquine in Healthcare Providers Highly Exposed to COVID-19

Withdrawn·UUniversidad Nacional de Colombia·Phase 3·NCT04346329

The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)

Unknown status·CCorpometria Institute·Phase 2/3·NCT04712279·294 enrolled

Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers

Terminated·—·Phase 3·NCT04328285·118 enrolled

Hydroxychloroquine to Prevent SARS-CoV-2 Infection/COVID-19

Completed·UUniversidad Peruana Cayetano Heredia·Phase 3·NCT04414241·68 enrolled

Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19

Completed·IIntermountain Health Care, Inc.·Phase 2·NCT04329832·85 enrolled

Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts

Completed·—·Phase 4·NCT04652648·54 enrolled

Post Exposure Prophylaxis in Healthcare Workers Exposed to COVID-19 Patients

Unknown status·HHamad Medical Corporation·Phase 2/3·NCT04437693·500 enrolled

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)

Completed·HHospital Israelita Albert Einstein·Phase 3·NCT04321278·440 enrolled

Assessing Hydroxychloroquine in Patients With SARS-CoV-2 (COVID-19)

Withdrawn·OOregon Health and Science University·Phase 2·NCT04363866

Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19

Completed·—·N/A·NCT04376814·40 enrolled

A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers

Unknown status·MMilitary Hospital of Tunis·Phase 3·NCT04377646·660 enrolled

Hydroxychloroquine for the Treatment of Mild COVID-19 Disease

Terminated·UUniversity Hospital Tuebingen·Phase 2·NCT04340544·17 enrolled

Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19

Unknown status·MMinistry of Health, Turkey·Phase 3·NCT04411433·1,008 enrolled

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting·UUniversity of Oxford·Phase 2·NCT05041907·3,800 enrolled

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT04605588·7 enrolled

International ALLIANCE Study of Therapies to Prevent Progression of COVID-19

Unknown status·NNational Institute of Integrative Medicine, Australia·Phase 2·NCT04395768·200 enrolled

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Suspended·FFundacion GenesisCare·N/A·NCT04394182·15 enrolled

Effectiveness of Hydroxychloroquine in Covid-19 Patients

Unknown status·PProf. Dr. Umar Farooq·Phase 3·NCT04328272·75 enrolled

COVID-19 PrEP HCW HCQ Study

Completed·NNYU Langone Health·Phase 2·NCT04354870·130 enrolled

Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19)

Completed·HHospital do Coracao·Phase 3·NCT04322123·667 enrolled

Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT04358068·20 enrolled

Hydroxychloroquine, Azithromycin in the Treatment of Covid-19

Unknown status·CCentre Hôpital Universitaire Farhat Hached·Phase 3·NCT04405921·200 enrolled

Treating COVID-19 With Hydroxychloroquine (TEACH)

Terminated·NNYU Langone Health·Phase 2·NCT04369742·128 enrolled

Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

Unknown status·PPost Graduate Institute of Medical Education and Research, Chandigarh·Phase 3·NCT04858633·1,000 enrolled

Hydroxychloroquine for Treatment of Non-Severe COVID-19

Unknown status·MMakerere University·Phase 2·NCT04860284·105 enrolled

Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

Unknown status·NNucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara·N/A·NCT04384458·400 enrolled

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

Completed·UUniversity of Chicago·Phase 1·NCT04351620·12 enrolled

Montelukast - a Treatment Choice for COVID-19

Completed·UUniversity of Sargodha··NCT04714515·150 enrolled

Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19

Terminated·UUniversity Hospital, Strasbourg, France·Phase 3·NCT04359953·16 enrolled

Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment

Completed·HHealth Institutes of Turkey·Phase 3·NCT04981379·1,120 enrolled

Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19

Terminated·HHugo Mendieta Zeron·Phase 4·NCT04341493·44 enrolled

Bacteriotherapy in the Treatment of COVID-19

Unknown status·UUniversity of Roma La Sapienza··NCT04368351·70 enrolled

Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19

Withdrawn·HHeinrich-Heine University, Duesseldorf·Phase 4·NCT04338906

Hydroxychloroquine Post-Exposure Prophylaxis for Coronavirus Disease (COVID-19) Among Health-Care Workers

Unknown status·RRambam Health Care Campus·N/A·NCT04438837·582 enrolled

Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel

Completed·PPlan Nacional sobre el Sida (PNS)·Phase 3·NCT04334928·1,002 enrolled

Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19)

Terminated·—·Phase 2/3·NCT04318444·10 enrolled

Rheumatoid Arthritis8 trials

Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)

Completed·UUniversity of Alabama at Birmingham·Phase 4·NCT00259610·755 enrolled

Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy

Completed·UUS Department of Veterans Affairs·N/A·NCT00405275·353 enrolled

Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis

Suspended·IIncannex Healthcare Ltd·Phase 2·NCT05942911·20 enrolled

Show 5 more trials

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

Completed· Roche logo

Roche·Phase 3·NCT01941095·100 enrolled

Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis

Completed·JJawaharlal Institute of Postgraduate Medical Education & Research·Phase 4·NCT02644499·186 enrolled

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT02603146·144 enrolled

Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis

Completed·—·Phase 3·NCT01132118·30 enrolled

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Recruiting·UUniversity of Nebraska·Phase 3·NCT03414502·400 enrolled

Pregnancy6 trials

Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum

Completed·BBarcelona Institute for Global Health·Phase 3·NCT04410562·129 enrolled

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

Unknown status·RRigshospitalet, Denmark·Phase 3·NCT03305263·186 enrolled

The Clinical Features and Pregnancy Outcomes of CTD Patients

Recruiting·QQilu Hospital of Shandong University··NCT04918524·126 enrolled

Show 3 more trials

The Clinical Features and Pregnancy Outcomes of RA Patients

Unknown status·QQilu Hospital of Shandong University··NCT05651373·100 enrolled

Treatment of Pregnancy RA

Unknown status·RRenJi Hospital·N/A·NCT04569890·100 enrolled

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

Withdrawn·UUniversity of Utah·Phase 2·NCT02379650

Efficacy and Safety5 trials

The Efficacy and Safety of HCQ Plus Pred in ANA Positive ITP

Recruiting·YYunfeng Cheng·N/A·NCT06479304·129 enrolled

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals

Withdrawn·—·Phase 3·NCT04349228

The Efficacy and Safety of HCQ Plus TPO-RA in ANA Positive ITP

Recruiting·YYunfeng Cheng·N/A·NCT06479291·126 enrolled

Show 2 more trials

The Efficacy and Safety of HCQ Plus DEX in ANA Positive ITP

Recruiting·YYunfeng Cheng·N/A·NCT06479317·129 enrolled

Efficacy and Safety of Baricitinib in Sjogren's Syndrome

Completed·PPeking Union Medical College Hospital·Phase 2·NCT05016297·87 enrolled

Melanoma4 trials

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

Completed·RRutgers, The State University of New Jersey·Phase 1·NCT00962845·20 enrolled

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma

Unknown status·UUniversitair Ziekenhuis Brussel·Phase 1/2·NCT03754179·63 enrolled

A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Completed·—·Phase 1·NCT01897116·8 enrolled

Show 1 more trial

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

Completed·—·Phase 1/2·NCT02257424·50 enrolled

89 more indications

Breast Cancer4 trials

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT03774472·15 enrolled

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

Recruiting·—·Phase 2·NCT04523857·66 enrolled

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT06328387·120 enrolled

Show 1 more trial

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Withdrawn·MMedical College of Wisconsin·Phase 1·NCT04316169

Prostate Cancer3 trials

Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer

Completed·SSt Vincent's Hospital, Sydney·Phase 1/2·NCT03513211·12 enrolled

Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance

Terminated·RRutgers, The State University of New Jersey·Phase 1·NCT02421575·4 enrolled

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT01828476·13 enrolled

Pneumonia3 trials

Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19

Completed·CCentro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva·Phase 3·NCT04420247·142 enrolled

Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial

Withdrawn·KKootenai Health·Phase 4·NCT04382625

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting·UUMC Utrecht·Phase 3·NCT02735707·20,000 enrolled

Pancreatic Cancer3 trials

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Completed·EEmory University·Phase 2·NCT04524702·10 enrolled

Hydroxychloroquine in Previously Treated Patients With Metastatic Pancreatic Cancer

Completed·—·Phase 2·NCT01273805·20 enrolled

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Completed·—·Phase 1/2·NCT01506973·119 enrolled

Multiple Myeloma2 trials

Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT01689987·18 enrolled

Combined Carfilzomib and Hydroxychloroquine in Patients With Relapsed/Refractory Multiple Myeloma

Completed·NNorwegian University of Science and Technology·Phase 1·NCT04163107·19 enrolled

Metastatic Colorectal Cancer2 trials

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

Completed·—·Phase 1·NCT03215264·20 enrolled

Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT01006369·38 enrolled

Type 2 Diabetes2 trials

Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes

Completed·UUniversity of Pittsburgh·Phase 4·NCT01326533·32 enrolled

Hydroxychloroquine in Type 2 Diabetes During Pregnancy

Recruiting·NNational University of Malaysia·N/A·NCT06319560·56 enrolled

Non-Small Cell Lung Cancer2 trials

Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II

Completed·RRutgers, The State University of New Jersey·Phase 2·NCT01649947·32 enrolled

Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)

Terminated·MMassachusetts General Hospital·Phase 1·NCT01026844·27 enrolled

Treatment2 trials

Hydroxychloroquine Treatment of Healthcare Workers With COVID19 Illness at Montefiore

Withdrawn·MMontefiore Medical Center·Phase 2·NCT04350450

a Retrospective Study on the Systemic Treatment of LPP and FFA

Completed·EErasmus Medical Center··NCT06512766·315 enrolled

Prophylaxis2 trials

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

Completed·UUniversity of Minnesota·Phase 3·NCT04308668·1,312 enrolled

Pre-exposure Prophylaxis for SARS-Coronavirus-2

Completed·UUniversity of Minnesota·Phase 3·NCT04328467·1,483 enrolled

Methotrexate2 trials

Targeted Treatment Early With Etanercept + Methotrexate vs.T2T Care for DMARD-naïve Early RA Patients Based on naïve T-cell Stratification

Unknown status·UUniversity of Leeds·Phase 4·NCT03813771·106 enrolled

Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy

Terminated·JJawaharlal Institute of Postgraduate Medical Education & Research·Phase 3·NCT02930343·136 enrolled

Telitacicept2 trials

Telitacicept Followed With Rituximab Therapy on APS Secondary to SLE

Unknown status·QQilu Hospital of Shandong University··NCT05644210·80 enrolled

Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients

Unknown status·FFen Li·Phase 4·NCT05666336·30 enrolled

ART2 trials

A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT04973566·48 enrolled

Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)

Unknown status·SSt Stephens Aids Trust·Phase 1·NCT01232660·12 enrolled

ESS2 trials

Immunosuppressant Regimens for Living Fetuses Study

Unknown status·RRenJi Hospital·N/A·NCT03671174·420 enrolled

IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA

Completed·UUniversity of Illinois at Chicago·Phase 4·NCT02451748·32 enrolled

HIV infection2 trials

Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection

Completed·SSEARCH Research Foundation·Phase 1/2·NCT02475915·15 enrolled

Inducing Immune Quiescence to Prevent HIV Infection in Women

Completed·UUniversity of Manitoba·N/A·NCT02079077·91 enrolled

Efficacy2 trials

The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients

Unknown status·OOslo University Hospital·Phase 2/3·NCT04321616·700 enrolled

Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients

Unknown status·MMedical Research Council·Phase 2·NCT01067417·83 enrolled

Solid Tumors2 trials

HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors

Completed·PPeng Wang, MD PhD·Phase 1·NCT02232243·10 enrolled

Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors

Completed·PPeng Wang, MD PhD·Phase 1·NCT03015324·38 enrolled

Renal Cell Carcinoma2 trials

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

Terminated·UUniversity of Pittsburgh·Phase 1·NCT01144169·7 enrolled

Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)

Completed·LLeonard Appleman·Phase 1/2·NCT01550367·30 enrolled

Antiphospholipid Syndrome2 trials

Hydroxychloroquine for Thrombosis Prevention and Antiphospholipid Antibody Reduction in Primary Antiphospholipid Syndrome

Completed·NNational and Kapodistrian University of Athens·N/A·NCT04153201·50 enrolled

Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome

Completed·UUniversity Hospital, Rouen·Phase 2·NCT02595346·25 enrolled

Colorectal Cancer2 trials

Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT02316340·42 enrolled

FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer

Completed·—·Phase 1/2·NCT01206530·50 enrolled

Leukemia1 trial

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

Terminated·—·Phase 1·NCT02631252·1 enrolled

Cognitive Function1 trial

Hydroxychloroquine and Cognitive Function After Surgery

Terminated·—·Phase 4·NCT03025087·24 enrolled

Immune Thrombocytopenia1 trial

Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia

Completed·—·Phase 4·NCT03229746·40 enrolled

Antibiotics1 trial

Antibiotics and Hydroxychloroquine in Crohn's

Completed·RRoyal Liverpool University Hospital·Phase 2·NCT01783106·59 enrolled

Primary Progressive Multiple Sclerosis1 trial

Hydroxychloroquine in Primary Progressive Multiple Sclerosis

Completed·UUniversity of Calgary·Phase 2·NCT02913157·35 enrolled

Heart1 trial

Preventive Approach to Congenital Heart Block With Hydroxychloroquine

Completed·NNYU Langone Health·Phase 2·NCT01379573·74 enrolled

Systemic Mastocytosis1 trial

Hydroxychloroquine in Isolated Cutaneous Mastocytosis Patients or Indolent Systemic Mastocytosis With Associated Skin Involvement Patients

Unknown status·UUniversity Hospital, Toulouse·Phase 2/3·NCT05084872·30 enrolled

Oral Lichen Planus1 trial

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

Completed·NNational Institute of Dental and Craniofacial Research (NIDCR)·Phase 2·NCT00102557·74 enrolled

Hepatitis1 trial

Using Hydroxychloroquine to Treat Nonalcoholic Steatohepatitis

Unknown status·NNational Taiwan University Hospital··NCT05733897·150 enrolled

Drug1 trial

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Completed· Sanofi logo

Sanofi·Phase 3·NCT01709578·546 enrolled

Insulin Secretion1 trial

The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion

Unknown status·HHadassah Medical Organization·Phase 1/2·NCT02910076·40 enrolled

Cardiomyopathy1 trial

The Effects of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy

Recruiting·TTongji Hospital·Phase 2/3·NCT05961202·200 enrolled

Advanced Cancer1 trial

Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01266057·143 enrolled

Dialysis1 trial

The Danish Pre-HCQ COVID Dialysis Study

Withdrawn·NNicholas Carlson·Phase 4·NCT05110651

Lupus Nephritis1 trial

Multicenter Registry of Pediatric Lupus Nephritis in China

Unknown status·XXiqiang Dang··NCT03791827·1,200 enrolled

Glioblastoma Multiforme1 trial

Hydroxychloroquine, Radiation, and Temozolomide Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT00486603·92 enrolled

Hepatocellular Carcinoma1 trial

Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma

Not yet recruiting·VVA Office of Research and Development·Phase 1/2·NCT05842174·93 enrolled

Hepatitis C1 trial

Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C

Terminated·BBioLineRx, Ltd.·Phase 1/2·NCT01833845·4 enrolled

Effectiveness1 trial

A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19

Completed·BBurnasyan Federal Medical Biophysical Center·Phase 2/3·NCT04347031·320 enrolled

Immune Checkpoint Blockade1 trial

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Terminated·—·Phase 1/2·NCT04214418·27 enrolled

Myeloid Leukemia1 trial

Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia

Unknown status·LLynn McMahon·Phase 2·NCT01227135·66 enrolled

Pericarditis1 trial

Hydroxychloroquine in Colchicine-Resistant Glucocorticoid-Dependent Idiopathic Recurrent Pericarditis

Unknown status·HHippocration General Hospital·Phase 3·NCT05737680·30 enrolled

Myelodysplastic Syndrome1 trial

CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

Withdrawn·WWake Forest University Health Sciences·Phase 1/2·NCT03929211

Myocardial Infarction1 trial

Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial

Completed·HHelsinki University Central Hospital·Phase 4·NCT02648464·125 enrolled

Small Cell Lung Cancer1 trial

STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)

Terminated·UUniversity College, London·Phase 2·NCT02722369·72 enrolled

Drug Repurposing1 trial

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine

Completed·—··NCT04691505·133,553 enrolled

Trial1 trial

Public Health Emergency: SOLIDARITY TRIAL Philippines

Completed·UUniversity of the Philippines·N/A·NCT05024006·1,314 enrolled

Endothelial Dysfunction1 trial

Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis

Completed·IIndonesia University·N/A·NCT03085940·37 enrolled

Baricitinib1 trial

Baricitinib in CPPD - the BAPTIST Study

Not yet recruiting·II.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio·Phase 2·NCT06768294·32 enrolled

TIA1 trial

Genetic Variants in Egyptian Patients Receiving HCQ(Hydroxychloroquine)

Unknown status·—··NCT03180190·50 enrolled

Nephropathy1 trial

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

Not yet recruiting·—·Phase 2·NCT06350630·334 enrolled

Cutaneous Lupus Erythematosus1 trial

Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion

Completed· Sanofi logo

Sanofi·Phase 3·NCT01551069·103 enrolled

Alopecia1 trial

The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)

Not yet recruiting·EErasmus Medical Center··NCT07190534·50 enrolled

Hepatocellular Cancer1 trial

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT03037437·64 enrolled

Parkinson's Disease1 trial

A Study to Evaluate Efficacy, Safety and Tolerability of Hydroxychloroquine in Subjects With Parkinson's Disease

Not yet recruiting·OOttawa Hospital Research Institute·Phase 2·NCT06816810·40 enrolled

Pancreatic Adenocarcinoma1 trial

Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma

Completed·CCancer Insight, LLC·Phase 1·NCT04787991·45 enrolled

Primary Sjögren's Syndrome1 trial

Therapeutic Effect of Upadacitinib in Primary Sjögren's Syndrome

Not yet recruiting·PPeking University People's Hospital·Phase 2·NCT06862284·30 enrolled

CLL1 trial

Hydroxychloroquine in Untreated B-CLL Patients

Terminated·NNorthwell Health·Phase 2·NCT00771056·23 enrolled

Metastatic Prostate Cancer1 trial

Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00786682·11 enrolled

Cystic Fibrosis1 trial

Hydroxychloroquine in Cystic Fibrosis

Completed·VVanderbilt University·Phase 1·NCT00311883·20 enrolled

Dexamethasone1 trial

Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

Completed·—·Phase 1·NCT01396200·6 enrolled

Severe Acute Respiratory Syndrome1 trial

Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Withdrawn·IInternational Brain Research Foundation·Phase 1·NCT04590274

Coronavirus1 trial

Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?

Terminated·MMegan Landes·Phase 3·NCT04374942·13 enrolled

Sudden Sensorineural Hearing Loss1 trial

Efficacy and Safety of Hydroxychloroquine in the Treatment of Sudden Sensorineural Hearing Loss

Not yet recruiting·—·Phase 2·NCT06467526·80 enrolled

COVID1 trial

Test and Treat COVID 65plus+

Withdrawn·UUniversity Hospital Tuebingen·Phase 2/3·NCT04351516

Cardiovascular Disease1 trial

Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study

Terminated·UUniversity of Arkansas·Phase 2·NCT01537315·8 enrolled

Outcome1 trial

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Completed·AAdrian Hernandez·Phase 3·NCT04334148·1,360 enrolled

Behcet's Disease1 trial

Hydroxychloroquine Efficacy on Behcet's Disease Thrombosis

Unknown status·—·N/A·NCT04022421·50 enrolled

Metastatic Solid Tumors1 trial

Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

Completed·—·Phase 1·NCT00909831·40 enrolled

Thrombocytopenia1 trial

Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE

Terminated·CChinese SLE Treatment And Research Group·Phase 3·NCT02444728·50 enrolled

Patients With Solid Tumors1 trial

Hydroxychloroquine in Treating Patients With Solid Tumors Undergoing Radiation Therapy for Bone Metastases

Terminated·VVirginia Commonwealth University·Phase 1·NCT01417403·10 enrolled

SARS CoV 2 Infection1 trial

Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

Terminated·—·Phase 2·NCT04335552·11 enrolled

Osteosarcoma1 trial

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03598595·31 enrolled

Type 2 Diabetes Mellitus1 trial

Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus

Terminated·—·Phase 2·NCT02303405·22 enrolled

Type 1 Diabetes Mellitus1 trial

Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT03428945·273 enrolled

Alopecia Totalis1 trial

Plaquenil for Alopecia Areata, Alopecia Totalis

Completed·HHordinsky, Maria K., MD·Phase 4·NCT00176982·16 enrolled

Advanced NSCLC1 trial

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT00977470·76 enrolled

Endothelial Function1 trial

Anti-Inflammatory Drug and Endothelial Function

Unknown status·IInstituto de Cardiologia do Rio Grande do Sul·Phase 4·NCT04161339·50 enrolled

Atopic Dermatitis1 trial

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not yet recruiting·UUniversity of California, San Francisco·Phase 4·NCT07352566·10 enrolled

Oral1 trial

Effects of Hydroxychloroquine on Oral Complaints of Sjögren Patients

Completed·—··NCT00873496·30 enrolled

Advanced Solid Tumors1 trial

Hydroxychloroquine + Vorinostat in Advanced Solid Tumors

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT01023737·72 enrolled

Patients With Advanced Solid Tumors1 trial

Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00813423·40 enrolled

Hidradenitis Suppurativa1 trial

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Completed·—·Phase 1/2·NCT03275870·17 enrolled

Prevention1 trial

Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT04344379·122 enrolled

Glioma1 trial

A Randomised Trial Investigating the Additional Benefit of Hydroxychloroquine(HCQ)to Short Course Radiotherapy (SCRT) in Patients Aged 70 Years and Older With High Grade Gliomas (HGG)

Completed·UUniversity College, London·Phase 2·NCT01602588·54 enrolled

Vasculitis1 trial

Hydroxychloroquine in ANCA Vasculitis Evaluation

Unknown status·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT04316494·43 enrolled

Ulcerative Colitis1 trial

Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

Active, not recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1/2·NCT05119140·3 enrolled

Erythema1 trial

The Efficacy and Safety of Anti-inflammation Treatment (Hirudoid Introduction Followed by Yellow Light Therapy) Combined With Tofacitinib and Doxycycline in Chinese Adult Patients With Mild to Moderate Erythematous Telangiectatic Rosacea

Recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine·N/A·NCT07343635·186 enrolled

Unspecified4 trials

Hydroxychloroquine Administration for Reduction of Pexophagy

Completed·TThe Hospital for Sick Children·Phase 2·NCT03856866·3 enrolled

Evaluation of Hydroxychloroquine to Prevent CIPN

Withdrawn·UUniversity of Arizona·Phase 2·NCT05689359

Very Early Versus Delayed Etanercept in Patients With RA

Completed·UUniversity of Leeds·Phase 4·NCT02433184·120 enrolled

Show 1 more trial

Double Therapy With IFN-beta 1b and Hydroxychloroquine

Completed·TThe University of Hong Kong·Phase 2·NCT04350281·60 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

PLAQUENIL

NDA NDA009768

Jan 14, 2022

SOVUNA

NDA NDA214581

Sources

References

[1]
ClinicalTrials.gov — 313 trial records for Hydroxychloroquine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Plaquenil drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Hydroxychloroquine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Hydroxychloroquine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA214581). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Jazz Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Toll-Like Receptor 7 Antagonist; Toll-Like Receptor 9 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Jazz Pharmaceuticals